Di Wang

Publication Activity (10 Years)

Years Active: 2019-2023
Publications (10 Years): 6

Top Topics

Metastatic Breast Cancer

Antiretroviral Therapy

Epidermal Growth Factor Receptor

Hepatitis C Virus

Top Venues

Cancer management and research

Journal of oncology

Drug design, development and therapy

This page only lists publications with an associated author ORCID identifier.

Publications

Han-Bing Li, Di Wang, Yue Zhang, Di Shen, Yi-Qun Che
IGFBP3 Enhances Treatment Outcome and Predicts Favorable Prognosis in ABC-DLBCL. Journal of oncology 2023 (2023)
Han-Bing Li, Di Wang, Yue Zhang, Di Shen, Yi-Qun Che
IGFBP3 Enhances Treatment Outcome and Predicts Favorable Prognosis in ABC-DLBCL. Journal of oncology 2023 (2023)
Yi-Qun Che, Yue Zhang, Kai-Ping Ou, Di Wang, Di Shen, Hui-Ying Liu, Yang Luo
Depth of Response and Early Tumor Shrinkage for Predicting Clinical Outcomes in HER2-Positive Metastatic Breast Cancer Treated with Trastuzumab. Cancer management and research 12 (2020)
Wen-Jie Wang, Di Wang, Mei Zhao, Xiao-Jie Sun, Yan Li, Hong Lin, Yi-Qun Che, Chang-Zhi Huang
Serum lncRNAs (CCAT2, LINC01133, LINC00511) with Squamous Cell Carcinoma Antigen Panel as Novel Non-Invasive Biomarkers for Detection of Cervical Squamous Carcinoma. Cancer management and research 12 (2020)
Yang Luo, Yue Zhang, Di Wang, Di Shen, Yi-Qun Che
Eradication of Hepatitis C Virus (HCV) Improves Survival of Hepatocellular Carcinoma Patients with Active HCV Infection - A Real-World Cohort Study. Cancer management and research 12 (2020)
Yi-Qun Che, Yue Zhang, Di Wang, Hui-Ying Liu, Di Shen, Yang Luo
Baseline Lymphopenia: A Predictor Of Poor Outcomes In HER2 positive Metastatic Breast Cancer Treated With Trastuzumab. Drug design, development and therapy 13 (2019)